Chemical Constituents of the Bark of Zanthoxylum gilletii (Rutaceae) and Their In Vitro Antiplasmodial and Molecular Docking Studies
Loading...
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Te phytochemical investigations of the methanol extract of Zanthoxylum gilletii bark led to the isolation of thirteen compounds
identifed as two alkaloids including one acridone 5-hydroxynoracronycine (1) and one benzo [c] phenanthridine decarine (2),
three lignans trans- and cis-fagaramide (3 and 4) and sesamin (5), two coumarins scoparone (6) and scopoletin (7), three
pentacyclic triterpenoids fridelin (8), lupeol (9) and erythrodiol-3-O-palmitate (10), one phenolic compound vanillic acid (11) as
well as two common steroids stigmasterol (12), and its derivative stigmasterol-3-O-β-D-glucopyranoside (13). Te structures of all
the isolated compounds were elucidated by means of their spectroscopic and spectrometric data (1D, 2D-NMR, MS) as well as the
comparison of these data with those reported in the literature. Except for compounds 9 and 11–13, all the other isolated
compounds are reported for the frst time from Z. gilletii but have been already obtained from other Zanthoxylum species and in
the Rutaceae family. Compounds 1, 3–5, and 9 were tested in vitro for their antiplasmodial potencies against Plasmodium
falciparum 3D7, and the results revealed that all the tested compounds displayed an inhibition between 51.89% and 54.69% while
only the mixture of 3 + 4 gave an IC50 lower than 10 000 nM (IC50 �1333 nM). Furthermore, all the compounds have been
evaluated in silico for their ability to inhibit the Plasmodium falciparum dihydroorotate dehydrogenase 5TBO. Sesamin (5) showed
the greatest afnity to the antiplasmodium receptor than artemether® and chloroquine®. Further recorded data from their
ADMET study, as well as their chemotaxonomy, are also discussed herein. Te present study provides further information to
enrich the chemistry of Z. gilletii and its qualifcation as an important source for good candidates in new antiplasmodial
drug development.